The FDA became aware of the problem after a patient submitted a complaint to the regulator that a vial of semaglutide from ...

A trial, targeted at people living with obesity from Britain to Puerto Rico, is the first head-to-head comparison of the ...

Rhythm Pharmaceuticals (RYTM – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst ...

Jim Cramer, the host of Mad Money, recently delved into the complexities of disappointing quarterly earnings, emphasizing the importance of transparent communication from management. He pointed out ...

There’s been lots of attention on type 2 diabetes drugs recently, especially since they might also be able to support weight ...

Viking Therapeutics' weight loss drug VK2735 may challenge Novo Nordisk and Eli Lilly's dominance in the obesity drug space ...

Our list of online Wegovy providers includes reputable brands with licensed healthcare providers who can support you on your ...

Novo Nordisk's (NVO) semaglutide, marketed as Wegovy for obesity, shows promise in reducing joint disease symptoms in ...

The Danish drugmaker plans to introduce a combination drug, CagriSema, that could result in 25% weight loss — higher than ...

Novo Nordisk NVO is expected to beat estimates when it reports third-quarter 2024 results on Nov. 6, before the opening bell.